PPB - Services

Complaints, Feedback and Enquiry

Medicine Quality Alert: Class II Medicines Recall of Galaxy’s Bupimax Heavy (Bupivacaine Hydrochloride in Dextrose Injection) Batch No. A24GL002, Manufactured by Nixi Laboratories Pvt, Ltd

The Pharmacy and Poisons Board has mandated the recall of Galaxy’s Bupimax Heavy (Bupivacaine Hydrochloride in Dextrose Injection) Batch No. A24GL002, Manufactured by Nixi Laboratories Pvt, Ltd.

From: Pharmacy and Poisons Board

Published: 30th April 2026

Recall Reference Number: REC/2026/011

Recall Classification: Class II

Recall Level: Retail/Facility Level

Manufacturer: Nixi Laboratories Pvt, Ltd

LTR: Galaxy Pharmaceutical Ltd

Product name: Galaxy’s Bupimax Heavy

Active Pharmaceutical Ingredient: Bupivacaine Hydrochloride in Dextrose Injection

Affected counties: All

Affected Batches

S/N

Batch No

Mfg Date

Exp Date

Pack Size

1.      

A24GL002

09/2024

08/2026

Ampoule

Brief description of the problem

Following Post Market Surveillance activities, the Board conducted sampling of Galaxy’s Bupimax Heavy (Bupivacaine Hydrochloride in Dextrose Injection) Batch No. A24GL002. Upon analysis, the product batch failed to comply with the specifications of the pH test whereby the pH was 3.7 against the specification of between 4.0 and 6.5.

Action for healthcare professionals

Quarantine all remaining stock and stop further distribution, sale, issuing, or use of Galaxy’s Bupimax Heavy (Bupivacaine Hydrochloride in Dextrose Injection) Batch No. A24GL002 immediately, and contact Galaxy Pharmaceutical Ltd to arrange return.

Action for patients and caregivers

Patients are advised to talk to their healthcare professional if they have the above batch of Galaxy’s Bupimax Heavy (Bupivacaine Hydrochloride in Dextrose Injection). 

Further Information

For any inquiries on consignments please contact Galaxy Pharmaceutical Ltd, by email at info@galaxypharma.co.ke or via telephone at +254 (0) 20 374 8551-2-3-4

Promptly report any case/s of suspected substandard and falsified products or adverse reactions or insufficient control of symptoms to the nearest healthcare facility or the Pharmacy and Poisons Board through the following channels:

For any further enquiries and feedback on the product recall, contact the post-marketing surveillance unit at the Pharmacy and Poisons Board via email at pms@ppb.go.ke

Download Document

Medicine Quality Alert: Class II Medicines Recall of Galaxy’s Bupimax Heavy (Bupivacaine Hydrochloride in Dextrose Injection) Batch No. A24GL002, Manufactured by Nixi Laboratories Pvt, Ltd
PMS Feedback Form
Full Name